FOLH1 and neoplasm: Indeed, the integration of PSMA‐targeting ligands onto different types of nanoparticles has previously been shown to enhance uptake and cargo delivery in PSMA+ tumor models in vivo.[26, 27, 28, 29] However, there are few, if any, published studies on the use of a PSMA‐nanobody as a targeting ligand for LNPs.